Featured Research

from universities, journals, and other organizations

Ethical, scientific issues related to 'post-market' clinical trials

Date:
July 13, 2010
Source:
Johns Hopkins Medical Institutions
Summary:
Amid growing concerns about clinical trials for drugs that have been approved by the FDA but are later linked to serious health risks, an independent committee at the Institute of Medicine has developed a conceptual framework to guide the agency through the tough decision of ordering such controversial "post-market" drug-safety trials.

Amid growing concerns about clinical trials for drugs that have been approved by the F.D.A. but are later linked to serious health risks, an independent committee at the Institute of Medicine led by two professors from Johns Hopkins University has developed a conceptual framework to guide the agency through the tough decision of ordering such controversial "post-market" drug-safety trials.

The recommendations of the committee, requested by the Food and Drug Administration, lay out a set of considerations that the F.D.A. can reference to ensure that clinical trials uphold ethical duties to trial participants. The committee also stresses that the agency be accountable to the public in its decision-making processes.

Presented on July 9 in a letter report to the F.D.A., the framework is organized around these recommendations:

  • The F.D.A. should determine if questions about possible risks or the risk-benefit balance of a drug or vaccine already on the market are serious enough to justify a policy decision, such as whether to revise the product's label.
  • A randomized, controlled trial of a drug linked to serious side effects should be conducted only when the existing scientific evidence and any evidence from new observational studies still do not supply the F.D.A. with enough data to make responsible policy decisions.
  • The agency should use "regulatory-science" principles and practices that emphasize public accountability and transparency when determining the need for a policy decision -- or the need for new knowledge to support a policy decision.
  • Such post-marketing trials to assess the safety and efficacy of approved drugs should be properly designed so that they minimize risk to patients and monitor risks on an ongoing basis. Any risks should first be judged as "acceptable" by appropriate oversight bodies.
  • Lastly, the F.D.A. and relevant oversight agencies should ensure that such trials have a comprehensive and meaningful informed-consent process in place, and one that continues over the course of the trials. Specifically, participants should be promptly advised of developments such as new research findings or changes in clinical practice that could affect their willingness to continue to accept the risks associated with a trial.

"The letter report was designed to provide general, broad guidance about some of the ethical issues that need to be taken into account by the F.D.A. in requiring post-market safety studies," says Ruth Faden, Ph.D., M.P.H., the committee's co-chair and the director of the Johns Hopkins Berman Institute of Bioethics.

The other co-chair is Steven Goodman, M.D., Ph.D., a professor of oncology in the Division of Biostatistics at the Johns Hopkins Kimmel Cancer Center and a core member of the Berman Institute faculty as well. Goodman is editor-in-chief of Clinical Trials: Journal of the Society for Clinical Trials and serves on the society's board of directors.

"The post-marketing context poses more difficult ethical and design challenges than we could address in this letter report," says Faden, a member of the Institute of Medicine (IOM). "We plan to take on these challenges in more detail in our full report."

The more immediate report responds to one of several questions that the F.D.A. asked IOM to explore in a review of ethical and scientific issues related to studying the safety of drugs on the market. The agency requested an initial report on the ethical issues in advance of a meeting it will hold July 13 and 14 to discuss the case of the diabetes drug Avandia.

The report covers some of the issues at play in the case but does address the specific controversies surrounding a large-scale clinical trial launched by the drug's maker, GlaxoSmithKline PLC.

A more detailed analysis of the issues discussed in the report, as well as their implications and effects, will be presented in the committee's final report, which is expected to be complete in the spring of 2011.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Ethical, scientific issues related to 'post-market' clinical trials." ScienceDaily. ScienceDaily, 13 July 2010. <www.sciencedaily.com/releases/2010/07/100712154436.htm>.
Johns Hopkins Medical Institutions. (2010, July 13). Ethical, scientific issues related to 'post-market' clinical trials. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/07/100712154436.htm
Johns Hopkins Medical Institutions. "Ethical, scientific issues related to 'post-market' clinical trials." ScienceDaily. www.sciencedaily.com/releases/2010/07/100712154436.htm (accessed July 30, 2014).

Share This




More Science & Society News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Britain Testing Driverless Cars on Roadways

Britain Testing Driverless Cars on Roadways

AP (July 30, 2014) British officials said on Wednesday that driverless cars will be tested on roads in as many as three cities in a trial program set to begin in January. Officials said the tests will last up to three years. (July 30) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
China's Drone King Says the Revolution Depends on Regulators

China's Drone King Says the Revolution Depends on Regulators

Reuters - Business Video Online (July 30, 2014) Comparing his current crop of drones to early personal computers, DJI founder Frank Wang says the industry is poised for a growth surge - assuming regulators in more markets clear it for takeoff. Jon Gordon reports. Video provided by Reuters
Powered by NewsLook.com
London Mayor Outlines 50-Year Vision Ahead of Population Rise

London Mayor Outlines 50-Year Vision Ahead of Population Rise

AFP (July 30, 2014) London Mayor Boris Johnson outlined his infrastructure plan for the British capital over the next 50 years on Wednesday, with a focus on how to cope with a population expected to reach 11 million. Duration: 00:57 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins